1. Distinct roles of TREM2 in central nervous system cancers and peripheral cancers.
- Author
-
Zhong, Jian, Xing, Xudong, Gao, Yixin, Pei, Lei, Lu, Chenfei, Sun, Huixin, Lai, Yanxing, Du, Kang, Xiao, Feizhe, Yang, Ying, Wang, Xiuxing, Shi, Yu, Bai, Fan, and Zhang, Nu
- Subjects
- *
CENTRAL nervous system cancer , *PERIPHERAL nervous system , *T-cell exhaustion , *MYELOID cells , *CENTRAL nervous system - Abstract
Glioblastomas (GBM) are incurable central nervous system (CNS) cancers characterized by substantial myeloid cell infiltration. Whether myeloid cell-directed therapeutic targets identified in peripheral non-CNS cancers are applicable to GBM requires further study. Here, we identify that the critical immunosuppressive target in peripheral cancers, triggering receptor expressed on myeloid cells-2 (TREM2), is immunoprotective in GBM. Genetic or pharmacological TREM2 deficiency promotes GBM progression in vivo. Single-cell and spatial sequencing reveals downregulated TREM2 in GBM-infiltrated myeloid cells. TREM2 negatively correlates with immunosuppressive myeloid and T cell exhaustion signatures in GBM. We further demonstrate that during GBM progression, CNS-enriched sphingolipids bind TREM2 on myeloid cells and elicit antitumor responses. Clinically, high TREM2 expression in myeloid cells correlates with better survival in GBM. Adeno-associated virus-mediated TREM2 overexpression impedes GBM progression and synergizes with anti-PD-1 therapy. Our results reveal distinct functions of TREM2 in CNS cancers and support organ-specific myeloid cell remodeling in cancer immunotherapy. [Display omitted] • TREM2 deficiency promotes tumor progression in murine glioblastoma (GBM) models • TREM2 downregulation is observed in individual GBM-infiltrated myeloid cells • AAV-mediated TREM2 overexpression represses GBM growth and synergizes with ICB • Lipidic damage signals causes a TREM2-mediated protective response in CNS cancers Zhong et al. show that TREM2 plays an immunoprotective role prompted by central nervous system-enriched sphingolipids during glioblastoma (GBM) progression. Single-cell and spatial sequencing revealed TREM2 downregulation in GBM-infiltrating myeloid cells. TREM2 overexpression represses GBM and synergizes with anti-PD-1 therapy. This study highlights organ-specific remodeling of myeloid cell targets in cancer immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF